Literature DB >> 11322171

Activity of the EBNA1 promoter associated with lytic replication (Fp) in Epstein-Barr virus associated disorders.

A A Brink1, C J Meijer, J M Nicholls, J M Middeldorp, A J van den Brule.   

Abstract

BACKGROUND/AIMS: In Epstein-Barr virus (EBV) positive cell lines that are stably infected, three different promoters are known to direct the transcription of EBV nuclear antigen 1 (EBNA1). These are located in the BamHI-C, BamHI-Q, and BamHI-F regions of the viral genome (Cp, Qp, and Fp, respectively). Fp is activated upon induction of the viral lytic cycle. The aim of this study was to investigate the activity of Fp in EBV associated diseases.
METHODS: Using reverse transcriptase polymerase chain reaction, a qualitative analysis of EBNA1 promoter usage in various EBV associated diseases was performed.
RESULTS: Fp driven transcription was detected in the context of primary infection and/or lytic replication; at least a portion of the Fp driven transcripts encoded EBNA1. Qp driven EBNA1 transcripts were detected in most samples across the range of disorders tested. Cp driven EBNA1 transcripts were detected in the context of immune suppression and in samples containing EBV positive (non-neoplastic) lymphoid cells.
CONCLUSIONS: These results confirm the previously proposed "housekeeping" function of the Qp promoter.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11322171      PMCID: PMC1187010          DOI: 10.1136/mp.54.2.98

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  39 in total

1.  The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated.

Authors:  J Sample; E B Henson; C Sample
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Authors:  A L Lear; M Rowe; M G Kurilla; S Lee; S Henderson; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

3.  Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site.

Authors:  J Sample; L Brooks; C Sample; L Young; M Rowe; C Gregory; A Rickinson; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

4.  Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes.

Authors:  B C Schaefer; M Woisetschlaeger; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

5.  Presence of Epstein-Barr virus harbouring small and intermediate-sized cells in Hodgkin's disease. Is there a relationship with Reed-Sternberg cells?

Authors:  N M Jiwa; P Kanavaros; P C De Bruin; P van der Valk; A Horstman; W Vos; H Mullink; J M Walboomers; C J Meijer
Journal:  J Pathol       Date:  1993-06       Impact factor: 7.996

6.  Replicative viral DNA in Epstein-Barr virus associated Burkitt's lymphoma biopsies.

Authors:  M I Gutierrez; K Bhatia; I Magrath
Journal:  Leuk Res       Date:  1993-03       Impact factor: 3.156

7.  Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency.

Authors:  L A Brooks; A L Lear; L S Young; A B Rickinson
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

8.  Epstein-Barr virus-associated gastric adenocarcinoma.

Authors:  D Shibata; L M Weiss
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

9.  Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts.

Authors:  L Brooks; Q Y Yao; A B Rickinson; L S Young
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.

Authors:  E M Deacon; G Pallesen; G Niedobitek; J Crocker; L Brooks; A B Rickinson; L S Young
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  7 in total

1.  Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection.

Authors:  Nirojini Sivachandran; Xueqi Wang; Lori Frappier
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

2.  Conserved mutation of Epstein-Barr virus-encoded BamHI-A Rightward Frame-1 (BARF1) gene in Indonesian nasopharyngeal carcinoma.

Authors:  Susanna H Hutajulu; Eveline K Hoebe; Sandra Awm Verkuijlen; Jajah Fachiroh; Bambang Hariwijanto; Sofia M Haryana; Servi Jc Stevens; Astrid E Greijer; Jaap M Middeldorp
Journal:  Infect Agent Cancer       Date:  2010-09-19       Impact factor: 2.965

3.  Functional analysis and molecular characterization of spontaneously outgrown human lymphoblastoid cell lines.

Authors:  Toralf Bernig; Nicole Richter; Ines Volkmer; Martin S Staege
Journal:  Mol Biol Rep       Date:  2014-07-19       Impact factor: 2.316

4.  Therapeutic vaccination against the rhesus lymphocryptovirus EBNA-1 homologue, rhEBNA-1, elicits T cell responses to novel epitopes in rhesus macaques.

Authors:  Eduardo L V Silveira; Mark H Fogg; Rachel M Leskowitz; Hildegund C Ertl; Roger W Wiseman; David H O'Connor; Paul Lieberman; Fred Wang; Francois Villinger
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

Review 5.  Epigenetic Impact on EBV Associated B-Cell Lymphomagenesis.

Authors:  Shatadru Ghosh Roy; Erle S Robertson; Abhik Saha
Journal:  Biomolecules       Date:  2016-11-24

Review 6.  The Epstein-Barr Virus EBNA1 Protein.

Authors:  Lori Frappier
Journal:  Scientifica (Cairo)       Date:  2012-12-19

7.  Prevalence of Epstein–Barr Virus Genotypes in Pakistani Lymphoma Patients

Authors:  Sadia Salahuddin; Jabbar Khan; Joharia Azhar; Christopher B. Whitehurst; Ishtiaq Qadri; Julia Shackelford; Joseph S Pagano; Dost Muhammad; Kristy L Richards
Journal:  Asian Pac J Cancer Prev       Date:  2018-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.